Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Mediwound ( (MDWD) ) is now available.
On August 18, 2025, MediWound Ltd. announced that its Chairman, Mr. Nachum (Homi) Shamir, and CEO, Mr. Ofer Gonen, purchased a total of 11,200 ordinary shares of the company in open market transactions. These purchases, made at an average price of $17.74 per share, were conducted in accordance with the company’s insider trading policy, reflecting confidence in the company’s future prospects and potentially influencing stakeholder perceptions positively.
The most recent analyst rating on (MDWD) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and cash flow issues. Technical analysis indicates bearish momentum, and valuation metrics are poor with a negative P/E ratio. The earnings call provided some positive developments, but financial challenges continue to weigh heavily on the company’s outlook.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. operates in the biotechnology industry, focusing on the development and commercialization of novel therapies for tissue repair and regeneration. The company is known for its innovative treatments aimed at improving healing processes, particularly in the field of burn and wound care.
Average Trading Volume: 64,259
Technical Sentiment Signal: Sell
Current Market Cap: $195.6M
For an in-depth examination of MDWD stock, go to TipRanks’ Overview page.